Healthcare Professionals

References

• Dhir V, Mohandas K. Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol. 1999;18(1):24-28.
• Zimmermann A. Pathology of Classical Pancreatic Cancer. In: Shrikhande S, Friess H, Buchler M, eds. Surgery of Pancreatic Tumors. 1st ed. New Delhi: BI Publications Pvt. Ltd.; 2008:41.
• Kim J, Lee K et. al. Clinical Usefulness of Carbohydrate Antigen 19-9 as a Screening Test for Pancreatic Cancer in an Asymptomatic Population. J Gastroenterol Hepatol 19(2):182-186, 2004. (Medscape)
• Iwao T, Hiyama E, Yokoyama T, et al. Telomerase activity for the preoperative diagnosis of pancreatic cancer. J Natl Cancer Inst 1997;89: 1621. (PubMed)
• Bahra M, Neumann U. Surgical Techniques for Resectable Pancreatic Cancer In: Riess H, Goerke A, Oettle H, eds. Pancreatic Cancer. Springer-Verlag Berlin Heidelberg 2008: 29-38.
• Kozuschek W, Reith H, Waleczek H, et. al. A comparison of long term results of the standard Whipple procedure and the pylorus preserving pancreatoduodectomy. J Am Coll Surg 1994; 178: 443-453.
• Kleef J, Michalski C, Buchler M, Fries H. Surgery for pancreas head adenocarcinoma. In Shrikhande S, Friess H, Buchler M, Surgery of pancreatic tumors, BI Publications Pvt. Ltd, 2008; 129- 138.
• Trede M et al. Personal observations, opinions, and approaches to cancer of the pancreas and the periampullary area. Surg Clin North Am 8:2001; 595-610. (Cross reference)
• Leach SD et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 85: 1998; 611-617. (Cross reference)
• Kalser M, Ellenberg S. Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120: 899.
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-277.
• Engineer R, Mahantshetty U, Shrivastava SK, Dinshaw KA. Radiation Therapy in Pancreatic Tumors. In: Shrikhande S, Friess H, Buchler M, Surgery of pancreatic tumors, BI Publications Pvt. Ltd, 2008; 334- 347.
• Burris H 3rd, Moore M, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403.
• Evans D, Abbruzzese J, Willett C. Cancer of the pancreas. In: deVita VT, Hellman S, Rosenberg SA, editors. Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins, 2001. p. 1126-61.
• Shore S, Raraty M, Ghaneh P, Neoptolemos J. Review article: Chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 2003;18:1049-69.
• Moertel C, Childs D Jr, Reitemeier R, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865.
• Moertel C, Frytak S, Hahn R, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705.
• Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751.
• Crane C, Abbruzzese J, Evans D, et al. Is the therapeutic index better with gemcitabine based chemoradiation than with 5-fluorouracil based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293.
• Poplin E, Levy D, Berlin J,etal. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer. J Clin Oncol 2006; 24:4004.
• Blaszkowsky L, Kulke K, Ryan D, et al. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 23:4099.
• Buchler M, Friess H, Malfertheiner P, et al. Studies of pancreatic cancer utilizing monoclonal antibodies. Int J Pancreatol 1990; 7:151-157.
• Hamilton S, Aaltonen L. WHO classification of tumor: Pathology and genetics. Tumors of the digestive system. 2000; 204-214.
• Zhou H, Schaefer N, Wolff M et al. Carcinoma of the Ampulla of Vater: Comparative Histologic/Immunohistochemical classification and follow-up. Am J Surg Pathol, 2004;28:875-882.
• Albores-Saavedia J, Henson D, Klimstra D. Atlas of tumor pathology: Tumors of gall bladder, Extrahepatic Bile Ducts and Ampulla of Vater. 3rd series, fascicle 27, Washington, DC: Armed Force Institute of Pathology, 2000:259-316.

<< Back to Top